A Bapsi Chakravarthy
Overview
Explore the profile of A Bapsi Chakravarthy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
3844
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Sherry A, Mayer I, Ayala-Peacock D, Abramson V, Rexer B, Chakravarthy A
Clin Breast Cancer
. 2020 Apr;
20(4):344-352.e1.
PMID: 32234364
Background: In a randomized trial (CREATE-X), patients with residual disease after standard neoadjuvant chemotherapy had improved survival with the addition of adjuvant capecitabine. For patients who required radiotherapy (RT), capecitabine...
12.
Chakravarthy A, Zhao F, Meropol N, Flynn P, Wagner L, Sloan J, et al.
Oncologist
. 2019 Dec;
25(5):e798-e807.
PMID: 31852811
Background: The addition of bevacizumab to chemotherapy improved outcomes for patients with metastatic colon cancer. E5204 was designed to test whether the addition of bevacizumab to mFOLFOX6, following neoadjuvant chemoradiation...
13.
Sherry A, von Eyben R, Newman N, Gutkin P, Mayer I, Horst K, et al.
Int J Radiat Oncol Biol Phys
. 2019 Dec;
108(1):268-276.
PMID: 31809877
Purpose: Patients with triple-negative breast cancer experience high rates of recurrence after radiation, which may be facilitated by the recruitment of circulating tumor cells to proinflammatory microenvironments in the absence...
14.
Xu J, Jiang X, Li H, Arlinghaus L, McKinley E, Devan S, et al.
Magn Reson Med
. 2019 Nov;
83(6):2002-2014.
PMID: 31765494
Purpose: Cell size is a fundamental characteristic of all tissues, and changes in cell size in cancer reflect tumor status and response to treatments, such as apoptosis and cell-cycle arrest....
15.
Rivin Del Campo E, Matzinger O, Haustermans K, Peiffert D, Glynne-Jones R, Winter K, et al.
Eur J Cancer
. 2019 Oct;
121:130-143.
PMID: 31574418
Purpose: Concomitant external-beam radiochemotherapy (5-fluorouracil-mitomycin C) has become the standard of care in anal cancer since the '90s. A pooled analysis of individual patient data from 7 major trials was...
16.
National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer
George T, Franke A, Chakravarthy A, Das P, Dasari A, El-Rayes B, et al.
Cancer
. 2019 Apr;
125(16):2732-2746.
PMID: 31017664
Colorectal cancer (CRC) represents a major public health problem as the second leading cause of cancer-related mortality in the United States. Of an estimated 140,000 newly diagnosed CRC cases in...
17.
Chakravarthy A
Int J Radiat Oncol Biol Phys
. 2017 Oct;
99(4):784-786.
PMID: 29063848
No abstract available.
18.
Abana C, Bingham B, Cho J, Graves A, Koyama T, Pilarski R, et al.
PLoS One
. 2017 Jul;
12(7):e0181725.
PMID: 28732081
Introduction: Although tumor metastases remain significant drivers of mortality, the genetic factors that increase the risks of metastases are not fully identified. Interleukin 6 (IL-6) has emerged as an important...
19.
Suntharalingam M, Winter K, Ilson D, Dicker A, Kachnic L, Konski A, et al.
JAMA Oncol
. 2017 Jul;
3(11):1520-1528.
PMID: 28687830
Importance: The role of epidermal growth factor receptor (EGFR) inhibition in chemoradiation strategies in the nonoperative treatment of patients with esophageal cancer remains uncertain. Objective: To evaluate the benefit of...
20.
Arneson K, Mondschein J, Stavas M, Cmelak A, Attia A, Horn L, et al.
J Neurooncol
. 2017 May;
133(2):435-442.
PMID: 28488066
We hypothesized that sorafenib (BAY 43-9006), an oral multi-kinase inhibitor, used in combination with SRS will improve overall intracranial control. This Phase I study assesses the safety, tolerability, and maximal...